Get the full picture
Sign in to uncover key details.
MB
Director, Manufacturing Operations
Get the full picture
Sign in to uncover key details.
Cellectar Biosciences
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
100 Campus Dr Ste 207, Florham Park, New...Phone Number
(608) 441-8120Website
www.cellectar.comRevenue
-Stock Symbol
CLRBIndustry
About Cellectar Biosciences
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.Explore more
Cellectar Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Cellectar Biosciences
Compare insights from companies similar to Cellectar Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Cellectar Biosciences Tech Stack
A closer look at the technologies used by Cellectar Biosciences
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cellectar Biosciences
Sign Up For FreeTo access detailed company insights
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study fo... Read More
